PEER-REVIEW REPORT

Name of journal: World Journal of Gastroenterology

Manuscript NO: 76810

Title: Effective combinations of anti-cancer and targeted drugs for pancreatic cancer treatment

Provenance and peer review: Invited Manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer’s code: 05698055

Position: Peer Reviewer

Academic degree: PhD

Professional title: Professor

Reviewer’s Country/Territory: China

Author’s Country/Territory: Japan

Manuscript submission date: 2022-04-01

Reviewer chosen by: AI Technique

Reviewer accepted review: 2022-04-12 14:28

Reviewer performed review: 2022-04-20 08:57

Review time: 7 Days and 18 Hours

- Scientific quality: [ ] Grade A: Excellent [Y] Grade B: Very good [ ] Grade C: Good
  [ ] Grade D: Fair [ ] Grade E: Do not publish

- Language quality: [ ] Grade A: Priority publishing [Y] Grade B: Minor language polishing
  [ ] Grade C: A great deal of language polishing [ ] Grade D: Rejection

- Conclusion: [ ] Accept (High priority) [ ] Accept (General priority)
  [ ] Minor revision [Y] Major revision [ ] Rejection

- Re-review: [ ] Yes [Y] No
SPECIFIC COMMENTS TO AUTHORS
Pancreatic cancer (PC) is one of the most common malignancies of the digestive tract worldwide, with increased morbidity and mortality. This review describes the combinations of gemcitabine and targeted drugs and the varieties of targeted drugs other than gemcitabine provides a comprehensive view of therapies in pancreatic cancer. However, the whole review still needs to be organized more concisely. The article is currently a simple summary of tons of work. Several important sections that should be mentioned such as clinical research and natural product research were missing. Critical points for lots of work were not extracted and organized well.
Name of journal: World Journal of Gastroenterology
Manuscript NO: 76810
Title: Effective combinations of anti-cancer and targeted drugs for pancreatic cancer treatment
Provenance and peer review: Invited Manuscript; Externally peer reviewed
Peer-review model: Single blind
Reviewer’s code: 05752663
Position: Peer Reviewer
Academic degree: MD, MSc
Professional title: Associate Professor
Reviewer’s Country/Territory: South Korea
Author’s Country/Territory: Japan
Manuscript submission date: 2022-04-01
Reviewer chosen by: AI Technique
Reviewer accepted review: 2022-04-26 19:25
Reviewer performed review: 2022-05-04 05:06
Review time: 7 Days and 9 Hours

<table>
<thead>
<tr>
<th>Scientific quality</th>
<th>Grade A: Excellent</th>
<th>[ Y] Grade B: Very good</th>
<th>[ ] Grade C: Good</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>[ ] Grade D: Fair</td>
<td>[ ] Grade E: Do not publish</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Language quality</th>
<th>[ Y] Grade A: Priority publishing</th>
<th>[ ] Grade B: Minor language polishing</th>
<th>[ ] Grade C: A great deal of language polishing</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>[ ] Grade D: Rejection</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Conclusion</th>
<th>[ ] Accept (High priority)</th>
<th>[ Y] Accept (General priority)</th>
<th>[ ] Minor revision</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>[ ] Major revision</td>
<td>[ ] Rejection</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Re-review</th>
<th>[ Y] Yes</th>
<th>[ ] No</th>
<th></th>
</tr>
</thead>
</table>
SPECIFIC COMMENTS TO AUTHORS
This mini-review articles give us comprehensive and well-organised information regarding gemcitabine-induced DNA damage response, and downstream signaling pathway, and the combinations of gemcitabine and targeted drugs. Thus, it will be of very interest to the readership. Thank you.